Kilitch Drugs (India)
Kilitch Drugs (India) Share Price Chart
Kilitch Drugs (India) last traded at ₹239.87 (2026-10-13). Over the past month the stock moved +31.7%, three months the stock moved +32.5%, year the stock moved +34.9%. Its closing range over 52 weeks is ₹128.35 – ₹261.80, with the latest close 8.4% below the high.
Closing prices up to 2026-10-13.
About Kilitch Drugs (India)
Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]
Business Overview:[1] KDL is a pharmaceutical company engaged in developing, manufacturing, marketing, and exporting various Pharmaceutical Formulations in dosage forms like Solid, Liquid, and Parental.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Kilitch Drugs (India) reported sales of ₹44.88 crore (+4.0%) and net profit of ₹1.96 crore (-13.7%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 44.88 | 2.94 | 6.55 | 1.96 | 0.83 |
| Mar 2026 | 89.60 | 22.14 | 24.71 | 14.88 | 4.15 |
| Dec 2025 | 53.81 | 6.15 | 11.43 | 4.31 | 1.27 |
| Sep 2025 | 48.92 | 5.04 | 10.30 | 8.04 | 2.34 |
| Jun 2025 | 43.14 | 3.26 | 7.56 | 2.27 | 0.87 |
| Mar 2025 | 61.23 | 14.59 | 23.83 | 10.22 | 2.97 |
| Dec 2024 | 56.17 | 8.73 | 15.54 | 5.61 | 1.70 |
| Sep 2024 | 47.47 | 6.10 | 12.85 | 8.61 | 2.46 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +15.2% | +76.7% | +36.6% | +29.0% | +3.1% | -4.2% | +46.3% | +4.0% |
| Operating profit growth | -29.2% | +282.9% | +106.1% | +96.4% | -17.4% | -29.6% | +51.7% | -9.8% |
| Net profit growth | +69.2% | +222.4% | +177.7% | +1963.6% | -6.6% | -23.2% | +45.6% | -13.7% |
| EPS growth | +82.2% | +104.8% | +188.3% | +128.9% | -4.9% | -25.3% | +39.7% | -4.6% |
| OPM % | 12.9% | 15.5% | 23.8% | 7.6% | 10.3% | 11.4% | 24.7% | 6.6% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Kilitch Drugs (India) reported sales of ₹235.00 crore (+18.7%) and net profit of ₹30.00 crore (+20.0%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 235.00 | 37.00 | 16.00 | 30.00 | 8.63 |
| Mar 2025 | 198.00 | 31.00 | 16.00 | 25.00 | 15.26 |
| Mar 2024 | 154.00 | 24.00 | 16.00 | 14.00 | 8.34 |
| Mar 2023 | 140.00 | 18.00 | 13.00 | 8.00 | 6.18 |
| Mar 2022 | 114.00 | 10.00 | 9.00 | 6.00 | 4.36 |
| Mar 2021 | 68.00 | 5.00 | 8.00 | 4.00 | 2.18 |
| Mar 2020 | 53.00 | 0.00 | 1.00 | 1.00 | 0.50 |
| Mar 2019 | 82.00 | 7.00 | 9.00 | 4.00 | 2.29 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +60.8% | -35.4% | +28.3% | +67.6% | +22.8% | +10.0% | +28.6% | +18.7% |
| Operating profit growth | +16.7% | -100.0% | – | +100.0% | +80.0% | +33.3% | +29.2% | +19.4% |
| Net profit growth | -20.0% | -75.0% | +300.0% | +50.0% | +33.3% | +75.0% | +78.6% | +20.0% |
| EPS growth | -33.8% | -78.2% | +336.0% | +100.0% | +41.7% | +35.0% | +83.0% | -43.4% |
| OPM % | 9.0% | 1.0% | 8.0% | 9.0% | 13.0% | 16.0% | 16.0% | 16.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Kilitch Drugs (India).
Get Free AI Stock Analysis FREE →Latest News
-
Kilitch Drugs Begins Operations at New Nutraceutical Facility; Shares Ease
-
Kilitch Drugs (India) Ltd: Technical Momentum Shifts Amid Mixed Signals
-
Kilitch Drugs Reports Strong Q4FY26 Results; Consolidated Revenue Rises to ₹8,960.27 Lakhs - scanx.trade
-
Kilitch Drugs (India) consolidated net profit rises 39.62% in the March 2026 quarter - Business Standard
-
Kilitch Drugs (India) consolidated net profit rises 39.62% in the March 2026 quarter - Business Standard
-
Kilitch Drugs (India) consolidated net profit rises 39.62% in the March 2026 quarter - Business Standard
-
Kilitch Drugs (India) Ltd. Schedules Board Meeting on May 15, 2026 to Approve Q4FY26 Financial Results - scanx.trade
Frequently Asked Questions
What is Kilitch Drugs (India)'s current stock price?
Kilitch Drugs (India) shares were last quoted at ₹239.87 (-0.7% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Kilitch Drugs (India)?
Kilitch Drugs (India) has a price-to-earnings (P/E) ratio of 25.99 and a price-to-book (P/B) ratio of 2.78. The industry P/E is 53.33.
What is the 52-week high and low of Kilitch Drugs (India)?
The 52-week high of Kilitch Drugs (India) is ₹233.50 and the 52-week low is ₹121.10.
What is the market cap of Kilitch Drugs (India)?
The market capitalisation of Kilitch Drugs (India) is about ₹781.57 crore.
How did Kilitch Drugs (India) perform in its latest quarterly results?
In the latest quarter (Jun 2026), Kilitch Drugs (India) reported sales of ₹44.88 crore (+4.0%) and net profit of ₹1.96 crore (-13.7%), compared with the same quarter last year.
Is Kilitch Drugs (India) a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Kilitch Drugs (India) has a 3-year ROE of 10.00%, 3-year profit growth of 38.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Kilitch Drugs (India)?
Promoters hold about 63.77% of Kilitch Drugs (India).
Which sector does Kilitch Drugs (India) belong to?
Kilitch Drugs (India) belongs to the Pharmaceuticals & Drugs sector.